XML 56 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
Year Ended December 31,
20242023
Revenue from collaborative arrangements and other contracts, including affiliated entity
$217,756 $832,010 
Less:
Research and development:
     INO-310729,930,344 17,840,728 
     INO-5401 and other Immuno-oncology6,293,401 11,758,935 
     Other programs (a)(77,955)18,701,675 
     Engineering and device-related19,393,929 8,863,170 
     Stock-based compensation2,821,226 4,606,341 
     Other unallocated expenses (b)17,259,395 24,905,714 
General and administrative36,996,338 47,582,104 
Impairment of goodwill— 10,513,371 
Total operating expenses112,616,678 144,772,038 
Interest income4,766,993 8,133,290 
Interest expense(177,833)(1,222,789)
Change in fair value of common stock warrant liability2,808,608 — 
(Loss) gain on investment in affiliated entity(1,166,443)773,145 
Net unrealized gain on available-for-sale equity securities2,077,182 5,850,626 
Other expense, net(3,163,711)(4,711,596)
Net loss$(107,254,126)$(135,117,352)

(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.
(b) Includes impairment of intangible assets of $2.0 million recorded in 2023.